There we go! My prediction is a peak in 2021 somewhere between $35 and $50 with a lot more upside to go in future years if all these planned Ph2 trials for other indications are successful. It will be good to know that there won't be a need to raise more funds via dilution (if EUA for CV19 pans out followed by HIV sales).